首页 | 本学科首页   官方微博 | 高级检索  
检索        


Clinical and genetic features of vascular Ehlers-Danlos syndrome
Authors:Germain Dominique P
Institution:1. University of Arkansas for Medical Sciences, Little Rock, AR;2. Saint Louis University Hospital, St. Louis, MO;3. Baylor Scott & White Medical Center, Grapevine, TX;4. Emory University School of Medicine, Atlanta, GA;1. Division of Vascular and Endovascular Surgery, University of Massachusetts Medical School, Worcester, Mass;2. Division of Infectious Disease, Massachusetts General Hospital, Boston, Mass;1. Division of Cardiothoracic Surgery, Department of Surgery, University of New Mexico Health Sciences Center, Albuquerque, NM;2. Division of Vascular Surgery, Department of Surgery, University of New Mexico Health Sciences Center, Albuquerque, NM;3. Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM;1. Servicio de Cardiología, Hospital General Universitario Gregorio Marañón, CIBERCV, Universidad Europea, Universidad Complutense, Madrid, España;2. Servicio de Cardiología, Hospital Clínico Universitario de Valencia, Universidad de Valencia, Valencia, España;3. Servicio de Cardiología, Hospital Universitario 12 de Octubre, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Universidad Complutense, Madrid, España
Abstract:Vascular Ehlers Danlos syndrome (EDS) is a rare autosomal dominant inherited disorder of connective tissue resulting from mutation of the COL3A1 gene encoding type III collagen. Affected individuals are prone to serious vascular, intestinal, and obstetrical complications. Complications are rare during infancy but occur in up to 25% of affected persons before the age of 20 and 80% before the age of 40. Median survival is 48 years. Arterial rupture accounts for most deaths. Intestinal perforation, usually involving the colon, are less fatal. Pregnancy is a high risk for women with EDS. As for many rare orphan diseases, delayed and/or improper diagnosis can lead to inadequate or inappropriate treatment and management. Diagnosis is based on clinical findings including specific facial features, thin translucent skin, propensity to bleeding, and rupture of vessels and/or viscera. Diagnosis can be confirmed either by biochemical assays showing qualitative or quantitative abnormalities in type III collagen secretion or by molecular biology studies demonstrating mutation of the COL3A1 gene. Varied molecular mechanisms have been observed with different mutations in each family. No correlation has been established between genotype and phenotype. Diagnosis should be suspected in any young person presenting with arterial or visceral rupture, carotid dissection, or colonic perforation. There are currently no specific treatments for EDS.
Keywords:
本文献已被 ScienceDirect PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号